faricimab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Age-Related Macular Degeneration, Diabetic Macular Edema, Wet Age-Related Macular Degeneration

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • Macular Edema Following Retinal Vein Occlusion (RVO)
Product first approved 2022Outside this platform's coverageFDA label
EU
  • Vabysmo (faricimab) for neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular oedema
Product first approved 2022antibodysociety.org
JP
  • Age-related macular degeneration associated with subfoveal choroidal neovascularization; diabetic macular edema
Product first approved 2022chugai-pharm.co.jp

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Age-Related Macular Degeneration
Diabetic Macular Edema
NCT04432831 · Hoffmann-La Roche
2020-08-05 – 2023-10-11 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT05904028 · Jaeb Center for Health Research
2023-11-09 – 2027-07-30 · Neovascular Age-related Macular Degeneration
What this study did
NCT04777201 · Hoffmann-La Roche
2021-04-19 – 2024-09-03 · Neovascular Age-related Macular Degeneration
What this study did
NCT05569148 · Hoffmann-La Roche
2022-10-17 – 2022-11-10 · Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
What this study did
Other / comorbidity
NCT06790784 · Jaeb Center for Health Research
2025-08-04 – 2032-02 · Proliferative Diabetic Retinopathy (PDR)
What this study did
NCT07922460 · University of Illinois Chicago
2026-12-01 – 2030-12-01 · Proliferative Sickle Cell Retinopathy
What this study did
NCT05844982 · Jaeb Center for Health Research
2023-11-21 – 2029-12-26 · Radiation Retinopathy, Visual Impairment
What this study did
NCT06176352 · Hoffmann-La Roche
2024-03-06 – 2026-05-22 · Choroidal Neovascularization Secondary to Pathologic Myopia
What this study did
NCT04740931 · Hoffmann-La Roche
2021-03-02 – 2023-07-12 · Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
What this study did
NCT04740905 · Hoffmann-La Roche
2021-03-02 – 2023-06-12 · Macular Edema, Branch Retinal Vein Occlusion
What this study did
Phase 2/3 (1)
Age-Related Macular Degeneration
NCT06572553 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-03-01 – 2024-08-31 · Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
What this study did
Phase 2 (7)
Age-Related Macular Degeneration
NCT07093385 · University of Baghdad
2024-09-10 – 2025-07-01 · Age-Related Macular Degeneration
What this study did
NCT03038880 · Hoffmann-La Roche
2017-01-27 – 2018-03-29 · Neovascularization, Choroidal, Macular Degeneration, Age-Related
What this study did
Diabetic Macular Edema
NCT04597918 · Hoffmann-La Roche
2020-11-25 – 2022-12-22 · Diabetic Macular Edema
What this study did
NCT02699450 · Hoffmann-La Roche
2016-04-27 – 2017-12-14 · Diabetic Macular Edema
What this study did
Other / comorbidity
NCT07681167 · Singapore National Eye Centre
2026-12 – 2029-08 · Central Serous Chorioretinopathy (CSC)
What this study did
NCT05681884 · Greater Houston Retina Research
2023-05-16 – 2026-02-26 · Non-Proliferative Diabetic Retinopathy
What this study did
Phase 1/2 (1)
Phase 1 (2)
Diabetic Macular Edema
NCT07425522 · Genentech, Inc.
2026-04-21 – 2028-11-17 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT01941082 · Hoffmann-La Roche
2013-12 – 2015-02 · Macular Degeneration
What this study did
Phase 4 (14)
Age-Related Macular Degeneration
NCT07403825 · Biobizkaia Health Research Institute
2026-05-25 – 2028-10 · Macular Degeneration, Age Related
What this study did
NCT07187804 · Kim's Eye Hospital
2025-09-23 – 2028-09-22 · Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
What this study did
NCT06742307 · Hospital Authority, Hong Kong
2025-08-21 – 2027-02-01 · Macular Degeneration Choroidal Neovascularization
What this study did
Diabetic Macular Edema
NCT07753616 · Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
2026-11-01 – 2029-11-01 · Diabetic Macular Edema
What this study did
NCT05224102 · Genentech, Inc.
2022-02-28 – 2027-01-26 · Diabetic Macular Edema
What this study did
NCT05610319 · McMaster University
2023-05-01 – 2026-12 · Diabetic Macular Edema
What this study did
NCT05610488 · Vista Klinik
2022-11 – 2023-12 · Diabetic Macular Edema
What this study did
Wet Age-Related Macular Degeneration
NCT07367282 · Junyeop Lee
2026-06-29 – 2028-12-31 · Macular Degeneration
What this study did
NCT06795048 · Hoffmann-La Roche
2025-03-14 – 2027-09-20 · Neovascular Age-related Macular Degeneration (nAMD)
What this study did
NCT06875245 · Faculty Hospital Kralovske Vinohrady
2023-03-31 – 2026-04 · Wet Age-related Macular Degeneration
What this study did
NCT05941715 · Medical University of Graz
2023-07-04 – 2025-02-26 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT06709339 · Association for Innovation and Biomedical Research on Light and Image
2025-08-06 – 2028-08 · Polypoidal Choroidal Vasculopathy
What this study did
NCT07695298 · Cincinnati Eye Institute, Southwest Ohio
2026-07 – 2028-05 · Presumed Ocular Histoplasmosis
What this study did
NCT06191094 · University of Colorado, Denver
2024-07-12 – 2028-01 · Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
What this study did
Early phase / not applicable (4)
Age-Related Macular Degeneration
NCT06929507 · University Hospital, Alexandroupolis
2025-03-10 – 2027-03-10 · Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
What this study did
Diabetic Macular Edema
NCT07520045 · Osijek University Hospital
2026-03-12 – 2027-06-01 · Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
What this study did
Wet Age-Related Macular Degeneration
Other / comorbidity
NCT07144865 · Bojie Hu
2024-12-01 – 2025-04-01 · Proliferative Diabetic Retinopathy
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Diabetic Macular Edema
NCT06908876 · Innovent Biologics Technology Limited (Shanghai R&D Center)
2025-04-24 – 2027-02-28 · Diabetic Macular Oedema
What this study did
Phase 1 (1)
Wet Age-Related Macular Degeneration
NCT07484074 · Ollin Biosciences, Inc.
2025-02-12 – 2025-12-09 · Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
What this study did

Competitive landscape

This drug's own stage for Age-Related Macular Degeneration: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Faricimab: this drugApprovedMultispecific antibodyAngiopoietin-2 / VEGF-APartial signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)ApprovedRNA AptamerComplement C5Reliable signal
NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165).
NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072)
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AWeak signalNo reviewed efficacy summary in this indication
Pegcetacoplan Ophthalmic (Syfovre)ApprovedPeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Verteporfin (Visudyne)ApprovedSmall moleculeBenzoporphyrin-derivative photosensitizer for photodynamic therapyPartial signal
NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed
NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
BAT5906Phase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HLX04-OPhase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg)
Surabgene LomparvovecPhase 3Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signal
NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed
MW02Phase 2/3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
BI 1584862Phase 2——not yet gradedNo reviewed efficacy summary in this indication
BI 771716Phase 2Antibody fragment—Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)Phase 2Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
ABBV-6628Phase 1/2Antibody fragmentComplement C5not yet gradedNo reviewed efficacy summary in this indication
SAR402663Phase 1/2Gene therapy / editingVEGFnot yet gradedNo reviewed efficacy summary in this indication
SAR446597Phase 1/2Gene therapy / editingComplement C1s + Factor Bbnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LazucirnonDiscontinuedSmall moleculeCCR3Partial signal
NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results).

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow faricimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Diabetic Macular EdemaActive not recruiting
Est. primary completion 2026-12 · NCT05610319 · CT.gov ↗
What to watch
Phase 4Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes MellitusEnrolling by invitation
Est. primary completion 2026-12 · NCT06191094 · CT.gov ↗
What to watch
2027 (3)
January 2027 (1)
Phase 4Diabetic Macular EdemaActive not recruiting
Est. primary completion 2027-01-26 · NCT05224102 · CT.gov ↗
What to watch
June 2027 (1)
Early phase / not applicableDiabetic Macular EdemaRecruiting
Est. primary completion 2027-06-01 · NCT07520045 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2027-07-30 · NCT05904028 · CT.gov ↗
What to watch
2028 (7)
April 2028 (1)
Phase 4Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-04-30 · NCT07367282 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4Presumed Ocular HistoplasmosisRecruiting
Est. primary completion 2028-05 · NCT07695298 · CT.gov ↗
What to watch
August 2028 (1)
Phase 4Polypoidal Choroidal VasculopathyRecruiting
Est. primary completion 2028-08 · NCT06709339 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2028-09-22 · NCT07187804 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-10 · NCT07403825 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1Diabetic Macular EdemaRecruiting
Est. primary completion 2028-11-17 · NCT07425522 · CT.gov ↗
What to watch
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-11-30 · NCT07461441 · CT.gov ↗
What to watch
2029 (5)
June 2029 (1)
Early phase / not applicableAge-Related Macular DegenerationRecruiting
Est. primary completion 2029-06 · NCT07249216 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Central Serous Chorioretinopathy (CSC)Not yet recruiting
Est. primary completion 2029-08 · NCT07681167 · CT.gov ↗
What to watch
November 2029 (1)
Phase 4Diabetic Macular EdemaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07753616 · CT.gov ↗
What to watch
December 2029 (2)
Phase 3Proliferative Sickle Cell RetinopathyNot yet recruiting
Est. primary completion 2029-12-01 · NCT07922460 · CT.gov ↗
What to watch
Phase 3Radiation Retinopathy, Visual ImpairmentRecruiting
Est. primary completion 2029-12-26 · NCT05844982 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 3Proliferative Diabetic Retinopathy (PDR)Recruiting
Est. primary completion 2032-02 · NCT06790784 · CT.gov ↗
What to watch

See the full readout calendar ↗